A quality improvement program involving protocolised reversal from neuromuscular block

Anaesthesia

Volumn 72, Issue 9, 2017, Pages 1152-1153

  McGill, N ^a   Yoon, M ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHESIST; CLINICAL PROTOCOL; HUMAN; LETTER; NEUROMUSCULAR BLOCKING; PREVALENCE; TOTAL QUALITY MANAGEMENT;

ANDROSTANE DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ANDROSTANOLS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; QUALITY IMPROVEMENT;

EID: 85027378354     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/anae.13957     Document Type: Letter

References (4)

1. Rodney G, Ball DR. Not just monitoring; a strategy for managing neuromuscular blockade. Anaesthesia 2015; 70: 1105–9.
2. Association of Anaesthetists of Great Britain and Ireland. Recommendations for standards of monitoring during anaesthesia and recovery 2015. Anaesthesia 2016; 71: 85–93.
3. Dubois PE, Mulier JP. A review of the interest of sugammadex for deep neuromuscular blockade management in Belgium. Acta Anaesthesiologica Belgica 2013; 64: 49–60.
4. Murphy GS, Szokol JW, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesthesia and Analgesia 2008; 107: 130–7.